Indication
Human Papillomavirus Type 16 Positive
1 clinical trial
2 products
Product
ISA101bClinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Cemiplimab